報價延遲最少15分鐘:2025/11/16 13:34 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.62 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.94/-2.79
|
|
企業價值
665.98M
|
| 資產負債 |
|
每股賬面淨值
0.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/16 13:34 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
